Navigation Links
Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
Date:4/9/2013

cturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire 's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

    References

    1. Shire HGT. Rare Disease Impact Report. http://www.rarediseaseimpact.com. Published April 2013.
    2. European Organisation for Rare Diseases (EURORDIS) website. "Rare Diseases: understanding this Public Health Priority." http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf. Accessed March 20, 2013.
    3. Global Genes website. "RARE Facts and Statistics." http://globalgenes.org/rarefacts/. Accessed March 20, 2013.

     


    '/>"/>
    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
    2. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    3. Shire Reaches Agreement in Principle With U.S. Government
    4. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    5. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    8. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    9. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    10. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    11. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/2/2015)... 2, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering and developing innovative therapies primarily ... today announced that Dr. Pamela Pavco , ... the 23 rd World Congress of ... include in-depth presentations by world-class clinicians and/or ...
    (Date:6/2/2015)... 2, 2015 MGB Biopharma ... resistance problem  MGB Biopharma, a biopharmaceutical ... to address the major global problem of antibiotic ... stable intravenous (IV) formulation of MGB-BP-3, designed for the ... The intravenous formulation of MGB-BP-3 is ...
    (Date:6/1/2015)... , June 1, 2015 ... ) has announced the addition of the ... (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, ... Flow Cytometry), End Users - Global Forecast ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
    (Date:6/1/2015)... June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... 31, 2015.  Biorem,s complete 2015 first quarter financial statements and MD&A ... Summary:Three-months ended March 31,(in CDN$,000 except per share data) ... , 1,974 Gross profit , 1,531 , ... earnings (loss) , 528 , (531) Basic earnings ...
    Breaking Biology Technology:RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
    ... Foundation for Angelman Syndrome Therapeutics (FAST) announces it will ... treatment for the rare genetic disorder, Angelman Syndrome (AS).  ... study will examine if the off label administration ... with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is ...
    ... Feb. 14, 2012  Milo Biotechnology will receive $250,000 ... assistance and some capital into early stage Northeast ... a therapy to increase muscle strength and improve ... Milo is the 61st company in JumpStart,s portfolio. ...
    ... Gen-Probe Incorporated (NASDAQ: GPRO ) today reported ... in the quarter grew 16%, to a new record of ... to a new high of $0.72. "Gen-Probe finished ... quarter while clinical diagnostics revenues continued their solid growth," said ...
    Cached Biology Technology:Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 2Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 3JumpStart Invests $250,000 in Milo Biotechnology 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15
    (Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
    (Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
    (Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
    Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
    ... Start-up awarded with an additional 100.000 Euros in financial ... opportunity to double the financial support through the execution ... 4th edition of the Building Global Innovators & continued ... 3rd edition of Building Global Innovators Venture Competition. The ...
    ... findings published in Pediatrics (Epub ahead of print) ... Disorders reveal that 70 percent of children with autism spectrum ... achieved phrase or fluent speech by age eight. This suggests ... at age four can be expected to make notable language ...
    ... perform only one job, but a new study by a ... recruit enzymes for other jobs to benefit medical fields and ... function in a cell, but many are capable of doing ... the beginning of a chemical reaction that they don,t ...
    Cached Biology News:Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 2Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 3Veniam is the winner of the major Portuguese Venture Competition 'Builidng Global Innovators' 4Speech emerges in children with autism and severe language delay at greater rate than thought 2Speech emerges in children with autism and severe language delay at greater rate than thought 3Promiscuous enzymes may be recruited to aid industry, medical fields 2
    Values of steady state parameters for enzyme activities are determined....
    ... Proliferator-Activated Receptor-gamma (PPAR) is a member ... ligand-activated transcription factors that heterodimerize with ... involved in the regulation of glucose ... (TZD) class of anti-diabetic agents called ...
    ... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
    ... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
    Biology Products: